Cargando…

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Detalles Bibliográficos
Autores principales:	Mastorino, Luca, Siliquini, Niccolò, Avallone, Gianluca, Ortoncelli, Michela, Quaglino, Pietro, Dapavo, Paolo, Ribero, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527684/ https://www.ncbi.nlm.nih.gov/pubmed/36199899 http://dx.doi.org/10.4081/dr.2022.9282

Ejemplares similares

Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study
por: Mastorino, Luca, et al.
Publicado: (2022)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022)

Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
por: Mastorino, Luca, et al.
Publicado: (2022)

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
por: MASTORINO, Luca, et al.
Publicado: (2022)

The Skin Microbiome and Its Role in Psoriasis: A Review
por: Celoria, Valentina, et al.
Publicado: (2023)

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study
por: Mastorino, Luca, et al.
Publicado: (2021)

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
por: Avallone, Gianluca, et al.
Publicado: (2023)

Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies
por: Ricci, Alessia Andrea, et al.
Publicado: (2023)

Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
por: Miniotti, Marco, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs
por: Burzi, Lorenza, et al.
Publicado: (2022)

Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
por: Mastorino, Luca, et al.
Publicado: (2022)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023)

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient
por: Quaglino, Pietro, et al.
Publicado: (2021)

Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center
por: Roccuzzo, Gabriele, et al.
Publicado: (2023)

Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report
por: Gelato, Federica, et al.
Publicado: (2022)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Alopecia areata after COVID-19 vaccination
por: Gallo, Giuseppe, et al.
Publicado: (2022)

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Immunotherapy in transplanted patients: A special population that can no longer be ignored
por: Rubatto, Marco, et al.
Publicado: (2021)

Guselkumab for plaque psoriasis
Publicado: (2019)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
por: Galluzzo, Marco, et al.
Publicado: (2020)

Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
por: Zhu, Yaowei, et al.
Publicado: (2020)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report
por: AGOSTINI, Andrea, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
por: Rubatto, Marco, et al.
Publicado: (2023)

Association between Primary Cutaneous B-cell Lymphomas and Other Skin Cancers: A Multicentre Cohort Study
por: AVALLONE, Gianluca, et al.
Publicado: (2022)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_omhqvknuhhsgdknbb45aauo91g